Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.
Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada.
Clin Rheumatol. 2024 Oct;43(10):3083-3088. doi: 10.1007/s10067-024-07099-9. Epub 2024 Aug 28.
Janus Kinase (JAK) inhibitors have emerged as a novel category of medications to treat a variety of immune-mediated conditions. However, limited insight exists regarding the impact of safety concerns on their usage and prescribing practices. Therefore, the objective of this study was to describe the utilization of JAK-inhibitors in Canada, both nationally and within individual provinces. We used data from IQVIA's Compuscript database. We conducted a repeated cross-sectional study of all JAK-inhibitor units dispensed in retail pharmacies (tofacitinib, ruxolitinib, baricitinib, and upadacitinib) within the ten Canadian provinces from July 1, 2016, to June 30, 2022. Throughout Canada, outpatient pharmacies dispensed an estimated total of 26,126,409 JAK-inhibitor units between 2016 and 2022, averaging 9,431 units dispensed per 100,000 population. All provinces had increasing rates of JAK-inhibitor units dispensed over time, whereby between July 2021 to June 2022, New Brunswick exhibited the highest rates (27,696 units per 100,000), and Prince Edward Island demonstrated the lowest rates (10,065 units per 100,000). In this study, utilization of JAK-inhibitors increased in Canada over the study period, evident at both provincial and national levels. Variability in JAK-inhibitor utilization between provinces underscores the necessity for further investigations to ascertain appropriate usage practices. Key Points • From 2016 to 2022, an estimated total of 26,126,409 JAK-inhibitor units were dispensed in retail pharmacies across Canada, with an average rate of 9,431 units dispensed for every 100,000 people in the population. • Tofacitinib was the most dispensed JAK-inhibitor during the entire study period, making up 76% of all units dispensed. Ruxolitinib, upadacitinib, and baricitinib made up 16%, 7.9%, and 1.1% of the JAK-inhibitor units dispensed, respectively. • The variance in provincial adoption of JAK-inhibitors across Canada might be influenced by several factors, including drug coverage availability, disease prevalence, and physician prescribing patterns.
Janus 激酶 (JAK) 抑制剂已成为治疗多种免疫介导疾病的一类新型药物。然而，对于安全问题对其使用和处方实践的影响，我们的了解有限。因此，本研究的目的是描述 JAK 抑制剂在加拿大的使用情况，包括全国范围内和各个省份的使用情况。
我们使用了 IQVIA 的 Compuscript 数据库中的数据。我们对 2016 年 7 月 1 日至 2022 年 6 月 30 日期间，加拿大十个省份的零售药店（托法替尼、鲁索利替尼、巴瑞替尼和 upadacitinib）中开出的所有 JAK 抑制剂单位进行了重复横断面研究。
在加拿大，2016 年至 2022 年期间，门诊药房估计共开出了 26126409 个 JAK 抑制剂单位，平均每 10 万人开出 9431 个单位。所有省份的 JAK 抑制剂开出单位数均随时间呈上升趋势，2021 年 7 月至 2022 年 6 月期间，新不伦瑞克省的开出单位数最高（每 10 万人 27696 个单位），爱德华王子岛省的开出单位数最低（每 10 万人 10065 个单位）。
在这项研究中，JAK 抑制剂的使用在研究期间在加拿大有所增加，在省级和国家级都有体现。各省之间 JAK 抑制剂使用的差异突出表明有必要进一步调查以确定适当的使用实践。
2016 年至 2022 年期间，加拿大各地零售药店共开出了估计总数为 26126409 个 JAK 抑制剂单位，平均每 10 万人中有 9431 个单位。
在整个研究期间，托法替尼是开出的最多的 JAK 抑制剂，占所有开出单位的 76%。鲁索利替尼、upadacitinib 和巴瑞替尼分别占开出的 JAK 抑制剂单位的 16%、7.9%和 1.1%。
加拿大各省对 JAK 抑制剂的采用差异可能受到多种因素的影响，包括药物覆盖范围的可用性、疾病流行率和医生的处方模式。
